Lnc-CNNM3-DT is a protective factor for CC and may influence the immune microenvironment in CC, potentially serving as a therapeutic target and a reliable biomarker for predicting the efficacy of immunotherapy in CC patients. Here, CNNM3 is linked to cholangiocarcinoma.